The Phase 2 LARA trial reported encouraging activity for pembrolizumab plus lenvatinib in recurrent gynaecological clear cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results